



Your partner  
in progress

2025-04-03

Hangzhou Singclean Medical Products Co., Ltd.  
No.125 (E),  
10th Street,  
Hangzhou Qiantang Area  
Zhejiang  
310018  
China

Our ref: EU 2024-1860/1097629

## Notified Body Confirmation Letter

### Reference: EU 2024-1860/1097629

To whom it may concern,

**Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain medical devices and in vitro diagnostic medical devices**

This letter confirms that, BSI Group The Netherlands B.V., a Notified Body (NB) designated against Regulation (EU) 2017/746 (IVDR) and identified by the number 2797 on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of IVDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of IVDR with the following manufacturer:

Hangzhou Singclean Medical Products Co., Ltd.  
No.125 (E),  
10th Street,  
Hangzhou Qiantang Area  
Zhejiang  
310018  
China

SRN Number: CN-MF-000014098

BSI Group The Netherlands B.V.  
Say Building John M. Keynesplein 1-27  
Amsterdam Bergen 1066 EP  
Netherlands  
[bsigroup.nl](https://www.bsigroup.nl)

+31 20 346 0780  
[BSIMedDev.NB2797@bsigroup.com](mailto:BSIMedDev.NB2797@bsigroup.com)

Validity of this letter may be verified by writing to [Certificate.Verification@bsigroup.com](mailto:Certificate.Verification@bsigroup.com)

BSI. All rights reserved. © 2024



The devices covered by the formal application and the written agreement mentioned above are identified in the Tables below. Table 1 identifies the devices for which an IVDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the Directive 98/79/EC. Table 2 identifies the devices for which an IVDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the Directive 98/79/EC.

In the case of devices covered by certificates issued under Directive 98/79/EC (IVD) that expired after 26 May 2022 and before 9<sup>th</sup> July 2024, without having been withdrawn, this letter also confirms that the manufacturer signed the written agreement under IVDR by the date of IVDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 54 of IVDR or Article 92 of the IVDR respectively, by the 9<sup>th</sup> July 2024 for the relevant devices.

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 110.3c of IVDR (as amended by (EU) 2024/1860), are shown below:

- 31 December 2027 for devices covered by an IVDD certificate regardless of their risk class under the IVDR
- For devices not requiring the involvement of a notified body under the IVDD, but requiring it under the IVDR and for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with Directive 98/79/EC, the following dates apply:
  - 31 December 2027, for class D devices;
  - 31 December 2028, for class C devices;
  - 31 December 2029, for class B devices and for class A devices placed on the market in sterile condition

On behalf of BSI Group The Netherlands B.V.,

Graeme Tunbridge

Senior Vice President, Medical Devices

BSI Group The Netherlands B.V.  
Say Building John M. Keynesplein 1-27  
Amsterdam Bergen 1066 EP  
Netherlands  
**bsigroup.nl**

+31 20 346 0780  
BSIMedDev.NB2797@bsigroup.com

Validity of this letter may be verified by writing to [Certificate.Verification@bsigroup.com](mailto:Certificate.Verification@bsigroup.com)



**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under Directive 98/79/EC:**

<b>Device name or Basic UDI-DI (under IVDR application)</b>	<b>IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)</b>	<b>If the IVDR device is a substitute device, identification of the corresponding IVDD device</b>	<b>IVDD Certificate Reference(s) of the devices under IVDR application, and the NB Identification</b>
<b>Not Applicable</b>	<b>Not Applicable</b>	<b>Not Applicable</b>	<b>Not Applicable</b>

**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive:**

<b>Device name or Basic UDI-DI (under IVDR application)</b>	<b>IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)</b>	<b>If the IVDR device is a substitute device, identification of the corresponding IVDD device</b>	<b>IVDD Certificate Reference(s) of the devices under IVDR application, and the NB Identification</b>
<b>COVID-19 Test Kit (Colloidal Gold Method)</b>	Class C	N/A	1434-IVDD-459/2021 NB 1434



## Confirmation Letter Revision History

Date	Action
2025-04-03	Initial issue

NB2797

BSI Group The Netherlands B.V.  
Say Building John M. Keynesplein 1-27  
Amsterdam Bergen 1066 EP  
Netherlands  
**bsigroup.nl**

+31 20 346 0780  
BSIMedDev.NB2797@bsigroup.com

Validity of this letter may be verified by writing to [Certificate.Verification@bsigroup.com](mailto:Certificate.Verification@bsigroup.com)